Had COVID - 19 symptoms in the last 2 days? Apply here to help us make testing accessible to all.
back to all FAQs

Is KnowNowᵀᴹ approved and safe?

The KnowNowᵀᴹ test has been developed to Vatic's stringent standards of quality and safety.

It has undergone the necessary clinical trials and performance tests and has been shown to meet the specific requirements published by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

The KnowNow test has been CE marked for professional use in a healthcare setting and has been registered for use in the UK and the EU.

Do you identify infection in people who are asymptomatic?

The KnowNowᵀᴹ test's unique detection mechanism identifies the infectiousness of the people tested. As a result, from our modelling based on accepted and peer-reviewed scientific literature, the KnowNowᵀᴹ test will detect asymptomatic people who are infectious with COVID-19.

The KnowNowᵀᴹ test has an impressively low limit of detection for an on-the-spot equipment-less test, of between 50,000 and 200,000 viral copies per mL, and so it is sensitive enough to identify infectious asymptomatic carriers even if they have low viral loads.

As the KnowNowᵀᴹ Test makes testing quicker, easier and more accessible, more people can get tested on an ongoing basis. Regular testing improves the chances of picking up asymptomatic carriers. Since the KnowNowᵀᴹ Test can detect the virus on day 3 to 4 after infection, based on KnowNow's low limit of detection and accepted models of viral load in disease progression, it identifies these carriers before they’re at a high risk of infecting other people.

Testing to identify asymptomatic carriers is so important, since they make up a large proportion of people who are infectious and enable the virus to keep spreading. This narrative review of 16 clinical studies around the globe concludes that between 40-45% of those infected with SARS-CoV-2 never develop symptoms, and that these asymptomatic carriers can infect others for an extended period, perhaps longer than 14 days.

We have a vaccine now, do we need testing anymore?

Although vaccine rollout is progressing extremely quickly in the UK, the government expects that it will be the end of July 2021 before every adult in the UK has been offered their first dose of a COVID-19 vaccine. Second doses should be received around 12 weeks after the first, and so it is likely to be the end of October 2021 before every adult has received both doses.

In the meantime, whilst we await full vaccine rollout, regular rapid antigen testing offers a way to enable the re-opening of society.

Beyond this, it is also important to consider that no vaccine is 100% effective even after 2 doses, that not everyone will accept or be able to have the vaccine, and that there is uncertainty as to whether the vaccines will work effectively against current or future mutations of the virus. We should also consider the fact that the UK is very much ahead of other countries around the world in progressing its vaccine rollout, and that it will still be some time before the vast majority of people globally will be vaccinated.

With these factors in mind, regular testing is likely to play a role in keeping societies safe and open for some time to come.

Does the KnowNow Test identify all COVID-19 mutations?

The mechanism underpinning the KnowNowᵀᴹ test mimics the means through which the virus interacts with the surface of a human cell in order to detect it. As a result, we expect that it will continue to identify the SARS-CoV-2 virus even in the face of further potential mutation in the future, unlike tests based on antibodies.

We have modelled the difference between the Wuhan and 501Y mutations in a recombinant protein model to give us initial analytical evidence that the KnowNow test reacts to these variations of concern. And we are currently carrying out a study on live samples of these and other mutations to gather practical evidence of this.

In fact, we predict that the KnowNowᵀᴹ test may potentially become even more sensitive as the virus mutates to become more infectious. And we will continue to carry out further analyses and studies to support this prediction, and confirm that KnowNow continues to function on newer mutations as they arise.

What is SARS-CoV-2?

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the name given by the International Committee on Taxonomy of Viruses (ICTV) to the virus responsible for causing the disease, COVID-19.

Why are you called Vatic?

The adjective "vatic" means "describing or predicting what will happen in the future," and derives directly from the Latin word vates, meaning "seer" or "prophet."

We chose this name as it speaks to our mission to make healthcare more proactive and empowering, through predictive screening for acute disease.

I've already activated my sample pack

If you have already activated your sample pack please go to the activation link that we emailed to you. Alternatively, if you fill in your email again we will re-send the activation link to you.

Is it possible to tell if the test has been carried out incorrectly?

Failed KnowNowᵀᴹ Test Result
Failed KnowNowᵀᴹ Test Result

Yes, it will be very clear if the test has been carried out incorrectly and failed.

If there are no lines at all visible in the KnowNowᵀᴹ device test results window, then the test has failed, and it should be repeated with a new device and a fresh saliva sample.

Who makes the KnowNow Test?

The KnowNowᵀᴹ Test has been invented, developed and manufactured in the UK by Senseutics Limited, trading as Vatic.

How do I order tests?

We're so pleased that you'd like to order our KnowNowᵀᴹ Tests. At the moment we are running some pilots with a few key partners, before distributing our tests more widely.

Please fill in our form and our team will get back to you.

How have you validated the accuracy of your tests?

To date we have conducted three clinical studies. The first was a UK Government-supported National Institute for Health Research (NIHR) study across ten UK hospitals; the second was with Liverpool School of Tropical Medicine, and the third is a community study that we have led ourselves. We have also carried out our own analytical assessments, as well as two Public Health England analytical assessments.

We have worked with over 300 negative patient samples and around 100 COVID-19 positive patients across our studies. We are also currently carrying out a 650+ patient clinical trial with sites in the UK, USA and Brazil to provide us with a higher volume of clinical data, and with a view to additional regulatory approvals to widen the reach of the impact we can have globally in pandemic recovery.

Had COVID - 19 symptoms in the last 2 days? Apply here to help us make testing accessible to all.